New Drug Approved for Early Alzheimer's
The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a new class of treatments that has been greeted with hope, disappointment and skepticism.The drug, donanemab, which will be sold under the brand name Kisunla, has been shown in studies to modestly slow the rate of cognitive decline in the early stages of the disease. It also had significant safety risks, including swelling and bleeding in the brain.Kisunla, made by Eli Lilly, is similar to another drug, Leqembi, that was approved last year. Both are intravenous infusions that target a protein implicated in Alzheimer’s, and both can slow the development of dementia by several months. Both also carry similar safety concerns. Leqembi, made by Eisai and Biogen, is given every two weeks; Kisun...